N Engl J Med 2018 Apr 15
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Related Questions
Patients with T3aN1a( stage IIIA per AJCC7) were excluded from nivolumab adjuvant trial. Would you consider nivolumab in these patients?
New answer by Medical Oncologist at Sediman Cancer Center/University Hospitals of Cleveland Case Medical Center (October 11, 2018)
This is a very timely and excellent question. There have been recently three landmark adjuvant studies, and two recent FDA approvals that have changed our approach for patient...
New comment by Medical Oncologist at Onc San Antonio ( February 27, 2023)
Thank you Dr. @Kaur.
New comment by Medical Oncologist at Emory University School of Medicine ( May 9, 2023)
Fully agree with Dr. @Wu's answer. The overall benefit of adjuvant immunotherapy in patients with IIB/IIC disease is not clear, especially considering the long-term side effec...
Which group of patients will benefit with observation versus adjuvant immunotherapy?
New answer by Medical Oncologist at The Ohio State University Comprehensive Cancer Center / James Cancer Hospital and Solove Research Institute (August 3, 2023)
Currently, there are FDA-approved adjuvant systemic therapy for stage III melanoma. These were based on the CheckMate 238 study (adjuvant nivolumab), KEYNOTE-054 (adjuvant pem...
Very-low-risk stage IIIA disease includes non-ulcerated lesions, primary ≤2 mm thickness, SLN metastasis <1 mm. Per NCCN the toxicity of adjuvan...
New comment by Medical Oncologist at Meritus Hematology & Oncology Specialists ( October 31, 2023)
Thank you for your input. Very helpful.